SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

SAN

80.79

+2.1%↑

UCB

272.5

-0.58%↓

SHL.DE

38.22

+1.25%↑

ARGX

705.8

+3.89%↑

VIE

35.35

+2.46%↑

Home・Aktien・Vetoquinol SA

Vetoquinol SA

Geschlossen

BrancheGesundheitswesen

79.2 0.64

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

78.5

Max

80.1

Schlüsselkennzahlen
By Trading Economics
Einkommen	25M
Verkäufe	10M 268M
KGV Branchendurchschnitt	15.373 66.418
Gewinnspanne	9.734
Angestellte	2,497
EBITDA	252M 301M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+37.16% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-7.1M 928M
Vorheriger Eröffnungskurs	78.56
Vorheriger Schlusskurs	79.2

Nachrichtenstimmung

By Acuity

50%

154 / 348 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

72.6 / 75.1 Unterstützung & Widerstand

Vetoquinol SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Apr. 2026, 23:25 UTC

Wichtige Nachrichtenereignisse

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13. Apr. 2026, 22:45 UTC

Wichtige Nachrichtenereignisse

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13. Apr. 2026, 18:03 UTC

Ergebnisse

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13. Apr. 2026, 23:58 UTC

Ergebnisse

Review & Preview: Earnings Time -- Barrons.com

13. Apr. 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13. Apr. 2026, 23:33 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13. Apr. 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13. Apr. 2026, 23:01 UTC

Ergebnisse

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13. Apr. 2026, 23:01 UTC

Ergebnisse

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13. Apr. 2026, 23:01 UTC

Ergebnisse

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13. Apr. 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13. Apr. 2026, 21:53 UTC

Ergebnisse

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13. Apr. 2026, 21:53 UTC

Ergebnisse

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13. Apr. 2026, 21:53 UTC

Ergebnisse

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13. Apr. 2026, 21:53 UTC

Ergebnisse

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13. Apr. 2026, 21:26 UTC

Wichtige Nachrichtenereignisse

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13. Apr. 2026, 21:23 UTC

Ergebnisse

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13. Apr. 2026, 21:16 UTC

Ergebnisse

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

13. Apr. 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13. Apr. 2026, 20:34 UTC

Ergebnisse

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13. Apr. 2026, 20:34 UTC

Ergebnisse

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13. Apr. 2026, 20:34 UTC

Ergebnisse

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13. Apr. 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13. Apr. 2026, 19:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13. Apr. 2026, 19:27 UTC

Market Talk

Wichtige Nachrichtenereignisse

Correction to Precious Metals Market Talk on April 9

13. Apr. 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13. Apr. 2026, 18:59 UTC

Market Talk

Wichtige Nachrichtenereignisse

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13. Apr. 2026, 18:59 UTC

Market Talk

Wichtige Nachrichtenereignisse

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13. Apr. 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Peer-Vergleich

Kursveränderung

Vetoquinol SA Prognose

Kursziel

By TipRanks

37.16% Vorteil

12-Monats-Prognose

Durchschnitt 110 EUR 37.16%

Hoch 110 EUR

Tief 110 EUR

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vetoquinol SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vetoquinol SA – Dist abgegeben haben.

Technischer Score

By Trading Central

72.6 / 75.1Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Stimmung

By Acuity

154 / 348 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.